Skip to main content
  1. Right Decisions
  2. Back
  3. Dermatology pathways
  4. Bowens
Announcements and latest updates

test announcement

Bowens

Warning

Bowen’s disease: Is a squamous cell carcinoma in situ. Rate of transformation into invasive SCC is approx. at least 3%. Common presentation in 7th decade on sun-exposed sites, e.g. head and neck and lower limbs. Well-demarcated scaling plaque. Aetiology includes UV, radiotherapy, viral (HPV 16), arsenic, immunosuppression, chronic injury or ulceration. 

Not all treatment options may be listed in this guidance. Please refer to local formulary for a complete list.

Treatment/ therapy

Mild:  

  • Advise all patients on use of sun protection and emollients.  

Active treatment options include: 

  • Topical Fluorouracil 5% (Efudix) cream apply 1-2 times daily for up to 4 weeks. Review 3 to 6 months after treatment to ensure healing has occurred. 
  • Cryotherapy – N.B.  use with caution on lower legs; consider shorter freeze time and repeat 4 weeks later, if required, to reduce risk of ulceration.  
  • Imiquimod 5% can be used as an alternative, on consultant advice.  

Moderate: 

  • Skin surgery: shave curettage and cautery, for solitary especially thicker or hyperkeratotic lesions or multiple lesions. 
  • Conventional PDT successful for solitary lesions. Consider daylight PDT for multiple lesions.   

Severe:  

Refer to a dermatologist if suspicious of invasive squamous cell carcinoma. Signs of this include a lesion that is growing rapidly, becoming thickened or raised and possibly tender to touch. Refer genital and perianal lesions suspicious of Bowen’s and periungual Bowen’s.  

Referral Management

Mild:  

Manage in primary care. Seek advice and guidance if there is diagnostic uncertainty. If confirmation is required before proceeding with a certain type of treatment, a punch biopsy can be performed.  This is preferable to a curette biopsy, as the full thickness of the epidermis and dermis can be viewed to establish whether there is any invasive disease amounting to a cutaneous SCC.

Moderate: 

Manage by those with training in primary care or refer to secondary care. Seek advice and guidance if there is diagnostic uncertainty.  If confirmation is required before proceeding with a certain type of treatment, a punch biopsy can be performed.  This is preferable to a curette biopsy, as the full thickness of the epidermis and dermis can be viewed to establish whether there is any invasive disease amounting to a cutaneous SCC. 

Severe:  

Refer to dermatology urgently. Many Dermatology services accept these under the USOC category. 

Clinical tips

  • For diagnostic purposes punch biopsy as opposed to curette to ensure full thickness evaluation. 
  • Bowen’s in genital and periungual sites higher risk for transformation to SCC. 
  • If any pigmentation, use two week wait referral guidance to exclude a melanoma. 

ICD search categories

Benign 

ICD11 code - 2E64 

Editorial Information

Last reviewed: 24/05/2023

Next review date: 24/05/2025

Author(s): Adapted from the BAD Referral Guidelines.

Version: BAD 1

Co-Author(s): Publisher: Centre for Sustainable Delivery, Scottish Dermatological Society .

Approved By: Scottish Dermatological Society